Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 787 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chemotherapy Induced Peripheral Neuropathy, Chemotherapy Induced Peripheral Neuropathy (CIPN), Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Neuropathic Pain
Interventions
SHIFT
Device
Lead sponsor
FluxWear, INC
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
Inebilizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
La Jolla, California • Loma Linda, California • Boston, Massachusetts + 1 more
Conditions
Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP
Interventions
Not listed
Lead sponsor
Charles M Knudson
Other
Eligibility
12 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Iowa City, Iowa
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Care for Patients With PSP and Related Disorders

NCT03552484
Conditions
Progressive Supranuclear Palsy, Dementia With Lewy Bodies, Multiple System Atrophy, Corticobasal Syndrome, Atypical Parkinson Disease
Interventions
Home Visit Program, Usual Care/Online Survey
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 2 Interventional Results available

Cranial Electrotherapy Stimulation in Burned Patients

NCT00723008
Conditions
Post Traumatic Stress Disorders, Burns
Interventions
Alpha Stim 100 (Cranial Electrotherapy Stimulation)
Device
Lead sponsor
United States Army Institute of Surgical Research
Federal
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Conditions
Generalized Anxiety Disorder
Interventions
At-Home Stimulation
Device
Lead sponsor
Electromedical Products International, Inc.
Industry
Eligibility
18 Years to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Choroid Plexus Neoplasm, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Ependymoma, Newly Diagnosed Childhood Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified, Recurrent Childhood Visual Pathway Glioma
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
1,258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
163
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 123 more
Conditions
Neurodegenerative Disease, Hereditary, Mitochondrial Diseases, Optic Atrophy
Interventions
Mutation analysis
Genetic
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
0 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Cutaneous Neurofibroma, Neurofibromatosis Type 1, Optic Nerve Glioma
Interventions
Laboratory Biomarker Analysis, Selumetinib Sulfate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Birmingham, Alabama • Bethesda, Maryland
Conditions
Progressive Supranuclear Palsy
Interventions
Davunetide, Placebo
Drug
Lead sponsor
Allon Therapeutics
Industry
Eligibility
41 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Conditions
NMO Spectrum Disorder, Spasticity, Muscle
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Michael, Levy M.D.,Ph.D.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Glaucoma, Glaucoma, Open-Angle, Optic Nerve Diseases
Interventions
Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy, image-guided radiation therapy, tomotherapy
Other · Radiation
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Vestibular Schwannoma, NF2, Neurofibromatosis 2, Acoustic Neuroma, Auditory Tumor
Interventions
lapatinib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Completed No phase listed Observational

Monitoring System for Cranial Orthoses

NCT06425172
Conditions
Plagiocephaly, Brachycephaly, Deformational Plagiocephaly, Deformational Posterior Plagiocephaly
Interventions
Cranial Remolding Orthosis
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Months to 18 Months
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Recruiting No phase listed Observational Accepts healthy volunteers

Trigeminal Neuralgia Electrophysiology

NCT05269472
Conditions
Trigeminal Neuralgia
Interventions
Trigeminal Electrophysiology
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Cerebrospinal Fluid Leak
Interventions
Acetazolamide
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Conditions
Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Parathyroid Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Thyroid Cancer, Recurrent Verrucous Carcinoma of the Larynx, Stage III Follicular Thyroid Cancer, Stage III Papillary Thyroid Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Larynx, Stage IIIB Non-small Cell Lung Cancer, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVA Basal Cell Carcinoma of the Lip, Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Follicular Thyroid Cancer, Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Lymphoepithelioma of the Oropharynx, Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVA Papillary Thyroid Cancer, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVB Basal Cell Carcinoma of the Lip, Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Follicular Thyroid Cancer, Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Lymphoepithelioma of the Oropharynx, Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVB Papillary Thyroid Cancer, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVC Basal Cell Carcinoma of the Lip, Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Follicular Thyroid Cancer, Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Lymphoepithelioma of the Oropharynx, Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVC Papillary Thyroid Cancer, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Thryoid Gland Nonmedullary Carcinoma, Thyroid Gland Medullary Carcinoma, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
gefitinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Central Nervous System Carcinoma
Interventions
Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
137
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more
Completed Not applicable Interventional Results available

Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)

NCT00382824
Conditions
Progressive Supranuclear Palsy
Interventions
Coenzyme Q10, Placebo
Dietary Supplement · Other
Lead sponsor
Lahey Clinic
Other
Eligibility
30 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Burlington, Massachusetts
Conditions
Cerebrospinal Fluid Leak
Interventions
FS VH S/D 500 s-apr, DuraSeal Dural Sealant
Drug · Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Springfield, Illinois • Springfield, Massachusetts • Detroit, Michigan + 7 more
Conditions
Progressive Supranuclear Palsy
Interventions
Pyruvate, creatine, niacinamide, Placebo
Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Not listed Not applicable Interventional Accepts healthy volunteers

Patient Augmented Reality and Vibratory Array Otorhinolaryngology Procedures

NCT06227039
Conditions
Pain, Acute, Vocal Fold Polyp, Vocal Cord Paralysis, Laryngeal Neoplasms
Interventions
Vibroacoustic stimulation on, Augmented Reality on, Vibroacoustic stimulation off, Augmented reality off
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia